Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

NCT00521404 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: CS-1008 (humanized anti-DR5 antibody)
DRUG: gemcitabine

Sponsor

Daiichi Sankyo